Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2026)
Roivant Sciences' Net Income towards Common Stockholders was -$189.84 million in fiscal Q1 2027 (quarter ended Jun 30, 2026), compared with -$223.36 million a year earlier.
Powered by 
Analysis
Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, Roivant Sciences' Net Income towards Common Stockholders was -$266.25 million through Jun 30, 2026; for FY2026 (ended Mar 31, 2026), it came in at -$299.77 million.
- In earlier fiscal years, Net Income towards Common Stockholders was -$171.98 million in FY2025, $4.35 billion in FY2024, -$1.01 billion in FY2023 and -$845.26 million in FY2022.
- Quarterly Net Income towards Common Stockholders has moved between -$352.01 million (fiscal Q3 2023) and $5.1 billion (fiscal Q3 2024) over five years.
- Per Business Quant data, ROIV's Net Income towards Common Stockholders in the three fiscal quarters before Q1 2027 was $302.99 million (Q4 2026), -$265.89 million (Q3 2026) and -$113.52 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Roivant Sciences | 25.81 Bn | 26.50 Bn | 1.16 Mn | -189.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -189.84 Mn |
| Mar 31, 2026 | 302.99 Mn |
| Dec 31, 2025 | -265.89 Mn |
| Sep 30, 2025 | -113.52 Mn |
| Jun 30, 2025 | -223.36 Mn |
| Mar 31, 2025 | -206.48 Mn |
| Dec 31, 2024 | 169.38 Mn |
| Sep 30, 2024 | -230.18 Mn |
| Jun 30, 2024 | 95.30 Mn |
| Mar 31, 2024 | -151.12 Mn |
| Dec 31, 2023 | 5.10 Bn |
| Sep 30, 2023 | -304.33 Mn |
| Jun 30, 2023 | -291.82 Mn |
| Mar 31, 2023 | -33.62 Mn |
| Dec 31, 2022 | -352.01 Mn |
| Sep 30, 2022 | -291.59 Mn |
| Jun 30, 2022 | -331.81 Mn |
| Mar 31, 2022 | -270.06 Mn |
| Dec 31, 2021 | -284.54 Mn |
| Sep 30, 2021 | -208.48 Mn |
API Access
Roivant Sciences Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ROIV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "ROIV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=ROIV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();